Adanate, a biotech company focusing on therapies in oncology and immunology, recently raised $30 million in a Series A financing, led by Westlake Village BioPartners and with participation from Avalon Ventures. Adanate's lead program (ADA-011) is a monoclonal antibody targeting a novel family of immune checkpoint receptors called leukocyte immunoglobulin-like receptors B (LILRB). The company is preparing to initiate clinical development of ADA-011 in 2022.

Wilson Sonsini Goodrich & Rosati advises Adanate on patent matters, including those related to this transaction. The team representing Adanate in this transaction is led by Uale Taotafa and includes Brett Zirkle and Mike Hostetler.

For more information, please see Adanate's website.